Gene expression profiling predicts clinical outcome of prostate cancer
J. Clin. Invest. Gennadi V. Glinsky, et al. 113:913 doi:10.1172/JCI20032 [
Go to this article.]
Figure 3Kaplan-Meier analysis of the probability that patients would remain disease-free among 79 prostate cancer patients constituting a signature validation group for all patients (A), patients with high (B) or low (C) preoperative PSA levels in blood according to whether they had good-prognosis or poor-prognosis signatures defined by the recurrence predictor algorithm, or whether they had high or low preoperative PSA level in the blood (D). Preoperative PSA level of 7.8 ng/ml was used as a cut-off discrimination level for patients’ stratification into poor- and good-prognosis subgroups. The cut-off values for each marker were identified through the detailed analysis of behavior of log-rank test
P values across the range of the measurements for each marker. We selected the prognosis discrimination cut-off value for each marker based on highest level of statistical significance in patients’ stratification into poor- and good-prognosis groups as determined by the log-rank test (lowest
P value and highest hazard ratio).
